|
1
|
Ghebranious N, Mukesh B, Giampietro PF,
Glurich I, Mickel SF, Waring SC and McCarty CA: A pilot study of
gene/gene and gene/environment interactions in Alzheimer disease.
Clin Med Res. 9:17–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Adlard PA, Tran BA, Finkelstein DI,
Desmond PM, Johnston LA, Bush AI and Egan GF: A review of β-amyloid
neuroimaging in Alzheimer's disease. Front Neurosci. 8:3272014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Piaceri I, Nacmias B and Sorbi S: Genetics
of familial and sporadic Alzheimer's disease. Front Biosci (Elite
Ed). 5:167–177. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alonso Vilatela ME, Lopez-Lopez M and
Yescas-Gomez P: Genetics of Alzheimer's disease. Arch Med Res.
43:622–631. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rao AT, Degnan AJ and Levy LM: Genetics of
Alzheimer disease. AJNR Am J Neuroradiol. 35:457–458. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Armstrong RA: What causes Alzheimer's
disease? Folia Neuropathol. 51:169–188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chang L, Wang Y, Ji H, Dai D, Xu X, Jiang
D, Hong Q, Ye H, Zhang X, Zhou X, et al: Elevation of peripheral
BDNF promoter methylation links to the risk of Alzheimer's disease.
PLoS One. 9:e1107732014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deng Y and Yu G: The effect of DNA
methylation on β-amyloid accumulation in Alzheimer's disease. Yi
Chuan. 36:295–300. 2014.(In Chinese). PubMed/NCBI
|
|
9
|
Ji H, Wang Y, Liu G, Xu X, Dai D, Chen Z,
Zhou D, Zhou X, Han L, Li Y, et al: OPRK1 promoter hypermethylation
increases the risk of Alzheimer's disease. Neurosci Lett.
606:24–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matthes HW, Maldonado R, Simonin F,
Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M,
Dollé P, et al: Loss of morphine-induced analgesia, reward effect
and withdrawal symptoms in mice lacking the mu-opioid-receptor
gene. Nature. 383:819–823. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gaveriaux-Ruff C, Matthes HW, Peluso J and
Kieffer BL: Abolition of morphine-immunosuppression in mice lacking
the mu-opioid receptor gene. Proc Natl Acad Sci USA. 95:6326–6330.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Wang YX, Liu T, Law PY, Loh HH,
Qiu Y and Chen HZ: µ-Opioid receptor attenuates Aβ
oligomers-induced neurotoxicity through mTOR signaling. CNS
Neurosci Ther. 21:8–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Levran O, Yuferov V and Kreek MJ: The
genetics of the opioid system and specific drug addictions. Hum
Genet. 131:823–842. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuzmin A, Bazov I, Sheedy D, Garrick T,
Harper C and Bakalkin G: Expression of pronociceptin and its
receptor is downregulated in the brain of human alcoholics. Brain
Res. 1305 Suppl:S80–S85. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peluso J, LaForge KS, Matthes HW, Kreek
MJ, Kieffer BL and Gaveriaux-Ruff C: Distribution of
nociceptin/orphanin FQ receptor transcript in human central nervous
system and immune cells. J Neuroimmunol. 81:1–192. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zaveri N: Peptide and nonpeptide ligands
for the nociceptin/orphanin FQ receptor ORL1: Research tools and
potential therapeutic agents. Life Sci. 73:663–678. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kruger C, Köthe L, Struppert A, Pietruck
C, Simm A and Grond S: Expression und function of the ORL-1
receptor on human leukocytes. Schmerz. 20:509–518. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
International Advisory Group for the
Revision of ICD-10 Mental and Behavioural Disorders, . A conceptual
framework for the revision of the ICD-10 classification of mental
and behavioural disorders. World Psychiatry. 10:86–92. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang D, Zheng D, Wang L, Huang Y, Liu H,
Xu L, Liao Q, Liu P, Shi X, Wang Z, et al: Elevated PLA2G7 gene
promoter methylation as a gender-specific marker of aging increases
the risk of coronary heart disease in females. PLoS One.
8:e597522013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu X, Ji H, Liu G, Wang Q, Liu H, Shen W,
Li L, Xie X, Zhou W and Duan S: A significant association between
BDNF promoter methylation and the risk of drug addiction. Gene.
584:54–59. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji H, Wang Y, Liu G, Chang L, Chen Z, Zhou
D, Xu X, Cui W, Hong Q, Jiang L, et al: Elevated OPRD1 promoter
methylation in Alzheimer's disease patients. PLoS One.
12:e01723352017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Conason AH and Sher L: Alcohol use in
adolescents with eating disorders. Int J Adolesc Med Health.
18:31–36. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Snyder SH and Childers SR: Opiate
receptors and opioid peptides. Annu Rev Neurosci. 2:35–64. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cai Z and Ratka A: Opioid system and
Alzheimer's disease. Neuromolecular Med. 14:91–111. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun Y, Sahbaie P, Liang D, Li W, Shi X,
Kingery P and Clark JD: DNA methylation modulates nociceptive
sensitization after incision. PLoS One. 10:e01420462015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou XL, Yu LN, Wang Y, Tang LH, Peng YN,
Cao JL and Yan M: Increased methylation of the MOR gene proximal
promoter in primary sensory neurons plays a crucial role in the
decreased analgesic effect of opioids in neuropathic pain. Mol
Pain. 10:512014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Viet CT, Dang D, Ye Y, Ono K, Campbell RR
and Schmidt BL: Demethylating drugs as novel analgesics for cancer
pain. Clin Cancer Res. 20:4882–4893. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Doehring A, Oertel BG, Sittl R and Lotsch
J: Chronic opioid use is associated with increased DNA methylation
correlating with increased clinical pain. Pain. 154:15–23. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang H, Wang F, Kranzler HR, Zhao H and
Gelernter J: Profiling of childhood adversity-associated DNA
methylation changes in alcoholic patients and healthy controls.
PLoS One. 8:e656482013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barg J, Belcheva M, Rowinski J, Ho A,
Burke WJ, Chung HD, Schmidt CA and Coscia CJ: Opioid receptor
density changes in Alzheimer amygdala and putamen. Brain Res.
632:209–215. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Butelman ER and Kreek MJ: Salvinorin A, a
kappa-opioid receptor agonist hallucinogen: Pharmacology and
potential template for novel pharmacotherapeutic agents in
neuropsychiatric disorders. Front Pharmacol. 6:1902015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cunningham CW, Rothman RB and Prisinzano
TE: Neuropharmacology of the naturally occurring kappa-opioid
hallucinogen salvinorin A. Pharmacol Rev. 63:316–347. 2011.
View Article : Google Scholar : PubMed/NCBI
|
